On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...

Gilead's Trodelvy and Merck's Keytruda improved progression-free survival in PD-L1+ metastatic TNBC in a Phase 3 trial with ...

The study enrolled patients with a PD-L1 combined positive score (CPS) of 10 or more, matching Keytruda's label in first-line ...

US biotech major Gilead Sciences (Nasdaq: GILD) today announced positive top-line results from the Phase III ...

Five-year data from the KEYNOTE-048 trial support the use of pembrolizumab and pembrolizumab-chemotherapy as standards of care, researchers wrote.

where tumours expressed PD-L1 (CPS ≥1). Patients who received the Keytruda and chemotherapy combination, with or without bevacizumab, enjoyed 19.8 months of overall survival compared to 16.3 ...

In the subset of patients whose tumors expressed PD-L1 (combined positive score [CPS] ≥10), median progression-free survival (PFS) improved from 15.2 months with standard chemotherapy ...

inoperable locally advanced or metastatic TNBC whose tumors express programmed cell death ligand 1 (PD-L1) (combined positive score [CPS] ≥10). Study participants were randomly assigned 1:1 to ...

The use of Trodelvy plus Keytruda in patients with previously untreated PD-L1+ metastatic TNBC is investigational, and the safety and efficacy of this use have not been established. The ...

Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 22C3 pharmDx (Code SK006) assay has received European IVDR ...